Refine your search
Collections
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Kaibada, Rajani
- New Stability Indicating RP-Ultra Fast Liquid Chromatographic Method for the Determination of Perampanel–An Antiepileptic Drug
Abstract Views :153 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutical Analysis and Quality Assurance GITAM Institute of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, Andhra pradesh-530045, IN
1 Department of Pharmaceutical Analysis and Quality Assurance GITAM Institute of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, Andhra pradesh-530045, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 6 (2019), Pagination: 2657-2663Abstract
A new RP-UFLC method has been developed and validated for the determination of Perampanel in its capsules using Shimadzu Model CBM-20A/20 Alite UFLC system (Shimadzu Co., Kyoto, Japan) equipped with SPD M20A prominence photodiode array detector on C8 (2) 100A (Luna) column (250 mm×4.60 mm i.d. 5μm particle size)maintained at room temperature. Mobile phase consisting of a mixture of water, acetonitrile and 0.1% acetic acid (50:50:0.1 v/v) was chosen with a flow rate of 1 mL/min (UV detection at 215nm) on isocratic mode. Perampanel obeys Beer-Lambert’s law over the concentration range 0.05–120 μg/mL with linear regression equation y=73084x+13800 (r2=0.9999). Forced degradation studies were performed and the method was validated as per ICH guidelines.Keywords
Perampanel, RP-UFLC, Stability Indicating, Validation, ICH Guidelines.
References
- Greenwood J, Valdes J. Perampanel (Fycompa) a review of clinical efficacy and safety in epilepsy. P. T. 41; 2016: 683-698.
- Franco V, Crema F, Iudice A, et al. Novel treatment options for epilepsy: focus on Perampanel. Pharmacol Res. 70; 2013: 35-40.
- Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug Perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 56; 2015:12-27.
- Ugo de Grazia, Annachiara D' Urso, Federica Ranzato, Valentina De Riva, Giorgia Contarato, Giuseppe Billo, Francesco Perini, Elisabetta Galloni. A liquid chromatography-mass spectrometry assay for determination of Perampanel and concomitant antiepileptic drugs in the plasma of patients with epilepsy compared with a fluorescent HPLC assay. Therapeutic Drug Monitoring. 40(4); 2018: 477-485.
- Mano Y, Takenaka O and Kusano K.High-performance liquid chromatography-tandem mass spectrometry method for the determination of Perampanel, a novel α- amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist in human plasma. J. Pharm. Biomed. Anal. 107; 2015: 56-62.
- Franco, Valentina; Marchiselli, Roberto; Fattore, Cinzia; Tartara, Elena; De Sarro, Giovambattista; Russo, Emilio; Perucca, Emilio. Development and validation of an HPLC-UV assay for the therapeutic monitoring of the new antiepileptic drug Perampanel in human plasma. Therapeutic. Drug Monitoring. 38(6); 2016: 744-750.
- Mano Y. An inter-laboratory cross-validation study for determination of Perampanel in human plasma by liquid chromatography assays. Biomedical Chromatography. 30(12); 2016: 2067-2069.
- Susan Mohamed, Carmina Candela, Roberto Riva and Manuela Contin. Simple and rapid validated HPLC-fluorescence determination of Perampanel in the plasma of patients with epilepsy. Practical Laboratory Medicine. 10; 2018:15-20.
- Mano Y, Takenaka O, Kusano K. HPLC with fluorescence detection assay of Perampanel, a novel AMPA receptor antagonist, in human plasma for clinical pharmacokinetic studies. Biomedical Chromatography. 29(10); 2015: 1589-1593.
- ICH Stability Testing of New Drug Substances and Products Q1A (R2), International Conference on Harmonization, 2003.
- ICH Validation of analytical procedures: Text and methodology Q2(R1), International Conference on Harmonization, 2005.